Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $14.29

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $14.2857.

Several equities research analysts recently weighed in on KPTI shares. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating and set a $8.00 target price (down from $12.00) on shares of Karyopharm Therapeutics in a research note on Monday, March 30th. Robert W. Baird reduced their target price on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright lowered their price target on Karyopharm Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th.

Karyopharm Therapeutics Price Performance

KPTI opened at $5.89 on Friday. The stock has a 50-day moving average price of $7.66 and a 200-day moving average price of $6.81. The firm has a market cap of $108.02 million, a PE ratio of -0.35 and a beta of 0.40. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million for the quarter, compared to analysts’ expectations of $33.16 million. As a group, sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics in the second quarter worth approximately $45,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth $56,000. Corient Private Wealth LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at about $74,000. Tudor Investment Corp ET AL purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at about $95,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $135,000. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.